SCHEMBL23218232

SCHEMBL23218232

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C)oc2ccc(-c3cccc(CN)c3O)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 3/20 0.35
GAA P10253 3/20 0.35
MAPT P10636 2/20 0.35
DPP4 P27487 2/20 0.35
PTGS2 P35354 1/20 0.35
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
FPR1 P21462 2/20 0.34
ALOX5 P09917 1/20 0.34
ANO1 Q5XXA6 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
GLA P06280 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CFD P00746 1/20 0.34
PTPN1 P18031 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852543 1.00 TSHR (0.40) TSHRMEN1KMT2AKDM4EALDH1A1
SCHEMBL23218205 0.92 TSHR (0.40) TSHRMEN1KMT2AKDM4EALDH1A1
SCHEMBL29852953 0.92 TSHR (0.40) TSHRMEN1KMT2AKDM4EALDH1A1
SCHEMBL29591873 0.91 CD274 (0.42) KDM4EGAAPOLBSMN1; SMN2ANO1
SCHEMBL23218311 0.91 CD274 (0.42) KDM4EGAAPOLBSMN1; SMN2ANO1
SCHEMBL23218633 0.88 ALDH1A1 (0.40) TSHRMEN1KMT2AKDM4EALDH1A1
SCHEMBL29853105 0.88 ALDH1A1 (0.40) TSHRMEN1KMT2AKDM4EALDH1A1
SCHEMBL23218533 0.87 CFD (0.43) TSHRMEN1KMT2AKDM4EALDH1A1
SCHEMBL29852791 0.87 CFD (0.43) TSHRMEN1KMT2AKDM4EALDH1A1
SCHEMBL23218525 0.85 ANO1 (0.36) TSHRMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885MEN1 1819/4885KMT2A 4445/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885MEN1 548/4885KMT2A 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.